Key result
Tailor antihypertensive selection to individual risk factors starting with low-dose, long-acting daily drugs or combinations.
Why the study?
All major classes of antihypertensive drugs are equally effective in reducing high blood pressure, but selection should consider patient risk factors, co-morbidities, safety, and tolerability to tailor treatment.
Antihypertensive therapy should be individualized based on patient comorbidities and risk factors, starting with low-dose, long-acting agents.
Answers are grounded in this paper and cite their sources.
Supports individualized selection per comorbidities; confirms JNC consensus but leaves open prospective validation in diverse cohorts.
The goal of antihypertensive treatment is to reduce both blood pressure and other risk factors for cardiovascular disease. There are currently six major classes of antihypertensive drugs that are available for the initial lowering and maintenance of blood pressure, including beta-blockers, alpha-adrenoceptor blockers, calcium channel blockers, diuretics, angiotensin-converting enzyme inhibitors and angiotensin-II receptor antagonists. All these classes of antihypertensive drugs are equally effective in reducing high blood pressure. To select the right antihypertensive drug, characteristics other than efficacy should be used to distinguish the different classes. According to the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the selection of initial antihypertensive drug should consider patient risk-factor profile and co-morbidity, as well as the safety and tolerability profile of the drug. When these factors are considered, an effective and well-tolerated drug regimen can be tailored to an individual patient. An initial drug regimen should consist of a low dose of a long-acting, once-daily drug that is titrated upward if blood pressure is not adequately controlled. Low-dose combinations of two antihypertensive drugs may also be considered. Results from comparative studies with different classes of antihypertensive drugs suggest that different populations of patients, such as those with diabetes, left-ventricular dysfunction, or lipid disorders, may benefit from taking different antihypertensive drugs.
No takes yet. Share an insight, caveat, or question.
Harry A.J. Struijker-Boudier (2003) conducted a review in Hypertension. Antihypertensive drugs was evaluated. Antihypertensive drug selection should be tailored to individual patient risk factors and comorbidities, starting with a low dose of a long-acting, once-daily drug or low-dose combinations.
Synapse has enriched 10 related papers. Consider them for comparative context: